Company*
(Country;
Symbol)

Company* (Country; Symbol)

Type/Product Area

Terms/Details (Date)

Achillion
Pharmaceuticals
Inc.*

Entomed
SA* (France)

Collaboration to discover and develop antiviral drugs

The partnership will focus on the discovery of lead compounds for the treatment of a number of viral diseases; Achillion will screen Entomed's library (4/9)

Achillion Pharmaceuticals Inc.*

Phytobiotech Inc.* (Canada)

Collaboration to discover drugs that address infectious disease targets

Phytobiotech will supply Achillion with purified, plant-derived small molecules called phytochemicals, which Achillion will screen through its infectious disease target assays; the companies will jointly develop any drug candidates that result (4/16)

Aeres
Biomedical Ltd.* (UK)

Acorda Therapeutics Inc.*

Agreement to generate two recombinant cell lines expressing human antibodies using Aeres' Supervector expression system

The two human antibodies are being developed by Acorda to promote regrowth and repair of the myelin sheath surrounding axons to restore neurological function in people with nervous system disorders (3/4)

Affinium Pharmaceuticals Inc.*

Albany Molecular Research Inc. (AMRI)

Agreement in which Albany Molecular Research will provide chemistry-based drug discovery expertise to augment Affinium's newly acquired anti-infective chemistry programs

Albany Molecular will receive fees and certain milestone payments (2/26)

Affitech AS* (Norway)

NatImmune AS* (Denmark)

Partnership in colon cancer with a goal to develop antibody drug leads being generated by Affitech for therapy and in vivo diagnostics against a NatImmune target

NatImmune will provide Affitech with access to the target; Affitech will apply its antibody libraries and its screening technologies to generate a panel of human antibodies against the target; the companies will develop candidates on a shared-cost, shared-revenue basis (4/9)

Affymetrix Inc. (AFFX)

Axon Instruments Inc. (ASX:AXN)

Agreement to develop an instrument to scan a future generation of Affymetrix GeneChip microarrays

Based on Axon's ImageXpress automated cellular screening platform, the instrument would scan GeneChip arrays formatted in multiwell plates (3/20)

Affymetrix Inc. (AFFX)

ParAllele
Bioscience*

Agreement under which Affymetrix will supply ParAllele with GeneChip Tag Arrays for use in combination with ParAllele's lab-in-a-tube assay technology for custom single nucleotide polymorphism genotyping

In the three-year, nonexclusive agreement, Affymetrix will supply catalog and custom-designed tag arrays to ParAllele for use in its commercial genotyping service business and with its pharmaceutical collaborators (3/18)

Ambion Inc.*

Cenix BioScience GmbH* (Germany)

Agreement to co-develop and commercialize the first human genome-wide siRNA library

The companies said they plan to update the library in accordance with the evolution of human genome sequence annotations (3/24)

Antares
Pharma Inc.
(ANTR)

GeneMedix plc (UK; LSE:GMX)

Collaboration for Antares to use its injection devices to support GeneMedix and its introduction of generic biopharmaceuticals in certain territories

Specific details were not disclosed (3/25)

Athelas SA* (Switzerland)

MerLion Pharmaceuticals Pte. Ltd.* (Singapore)

Two-year drug discovery and preclinical research collaboration to identify drug candidates in the areas of anti-virulence anti-infectives

MerLion will identify and characterize lead candidates from its samples using Athelas assays;Athelas will progress those compounds through initial preclinical development; the companies will share in the rights and development costs for lead optimization, clinical development and commercialization (4/9)

Benitec Ltd. (Australia;
ASX:BLT)

Tranzyme
Inc.*

Collaboration agreement to jointly develop and market their gene silencing and gene delivery technologies

Both parties will share revenues from the collaboration and also will develop targets using the combined technology for future joint commercialization (2/27)

bioMerieux SA* (France) (Canada;VSE:TMC)

Tm Bioscience Corp. Factor II (prothrombin) and Factor V Leiden gene patents in Tm's recently launched Tag-It Mutation Detection kits for coagulation disorders

Nonexclusive license agreement to use bioMerieux's

Tm expects to launch the kits this year (3/3)

Biosite
Inc. (BSTE)

Neurocrine Biosciences Inc. (NBIX)

Agreement for Biosite to use its Omniclonal phagedisplay technology to generate high-affinity antibodies to Neurocrine drug targets

Neurocrine expects to use the antibodies in discovery research programs; Biosite gets worldwide diagnostic licenses under Neurocrine's rights to various stroke targets selected by Biosite; Neurocrine will provide targets for up to three years; Biosite will receive development fees upon delivery of target-specific antibodies and has the potential to receive milestone payments (2/20)

Boston Scientific Corp. (NYSE:BSX)

Osiris Therapeutics Inc.*

Alliance to develop and commercialize a therapy to treat cardiovascular disease

The alliance includes an equity investment by Boston Scientific in Osiris (3/11)

Cangene Corp. (Canada;TSE:CNJ)

Twinstrand Therapeutics Inc.* (Canada)

Agreement aimed at improving Canada's readiness in the event of chemical, biological, radiological or nuclear incidents

The project is government funded; the partners intend to develop antibody-based therapies for individuals exposed to ricin (4/23)

Cellectis SA* (France)

Deltagen
Inc. (DGEN)

Worldwide, nonexclusive licensing agreement for a patent family relating to a process for the specific replacement or insertion of a gene in the receiver genome by homologous recombination

Cellectis granted Deltagen the right to use its technologies for in vitro and in vivo modifications and manipulations of the genetic material of rodents (4/1)

Cellectis SA* (France)

Nucleis
SA* (France)

Nonexclusive license agreement granting Nucleis a family of patents relating to a process for the insertion of a gene into the receiver genome by homologous recombination in mice

Nucleis gained the right to use Cellectis' technologies to engineer mice cell lines and generate mice as animal models (4/16)

Ceregene Inc.*

Genentech Inc. (NYSE:DNA)

Licensing agreement with Genentech gaining exclusive worldwide rights to genes expressing two nervous system growth factors for use in neurological gene therapies employing certain viral vectors

Genentech has an option to become Ceregene's development and marketing partner for NT-4/5 gene therapy upon completion of Phase II studies, after paying Ceregene an opt-in fee and milestone payments (3/26)

ChemNavigator
Inc.*

Chiron
Corp. (CHIR)

Agreement to work together in the area of virtual screening against Chiron's 3-D model of a hepatitis C drug target

The collaboration is designed to identify biologically active compounds to be developed for hepatitis C; the deal includes success fees and potential milestone payments for ChemNavigator (3/4)

Definiens AG* (Germany)

WITA GmbH* (Germany)

Partnership to develop and sell integrated proteomics solutions

The companies will combine gel analysis software from Definiens with optimized gels from WITA into a product for proteomic analysis (4/16**)

DeNovo Pharmaceuticals Ltd.* (UK)

Peakdale Molecular Ltd.* (UK)

Joint collaboration to exploit their respective skills in molecular design and chemistry synthesis

The first objective is to make available from Peakdale a range of screening compounds suitable for use in lead discovery, initially targeted at subfamilies within the GPCR superfamily (4/1)

Genesis Research and Development Corp. Ltd. (New Zealand; ASX:GEN)

EvoGenix Pty. Ltd.* (Australia)

Collaboration to undertake a joint research and development program to discover anti-inflammatory drugs

Both parties will screen and test sequences in a library of antibody-like molecules to identify inhibitors of specific biological activities (4/14)

Genetic TechnologiesLtd. (Australia; ASX:GTG)

Pyrosequencing AB (Sweden; SSE: PYROA)

Nonexclusive licensing agreement to noncoding DNA analysis and mapping patents belonging to Genetic Technologies with application to all genes and all species, to be used in applications of Pyrosequencing's sequencing by synthesis technology

Genetic Technologies gained $500,000 up front, plus royalties on reagent sales; it also will receive three Pyrosequencing instruments and intellectual property for use in Australia and New Zealand; the deal is worth $2.5M (3/12)

Genomics One Corp. (Canada; VSE:GNX)

Promega Corp.*

Agreement to enable Genomics One to better meet the needs of laboratories involved in genetic engineering

Further details were not disclosed (2/28)

Genzyme
Biosurgery
(GZBX)

Excigen Inc.*

Collaboration to provide a treatment for atrial fibrillation and to develop a natural pacemaker that could take the place of an electronic device in some patients

Genzyme Biosurgery will get an equity investment in Excigen (3/25)

Geron
Corp. (GERN)

PanCel Corp.*

Agreement granting PanCel a nonexclusive license to use its human telomerase reverse transcriptase technology for the replicative immortalization of human pancreatic islet cells

Geron received undisclosed up-front payments of cash and equity in PanCel, and would receive a share of proceeds from future product sales (3/6)

Gliatech Inc. (GLIAQ)

Solentix BioSciences Inc.*

Agreement for the purchase of an anti-inflammatory research platform from Gliatech

Financial terms were not disclosed (3/7)

Gradipore Ltd. (Australia;
ASX:GDP)

Serologicals Corp. (SERO)

Development agreement for evaluating the application of Gradipore's Gradiflow separations technology for the isolation of plasma proteins intended for use as diagnostic reagents, culture medium supplements or therapeutic indications

Upon successful completion of the evaluation to the specified requirements of Serologicals, the companies will discuss a more extensive commercial agreement for the purification and commercialization of other plasma proteins (2/25)

Graffinity AG* (Germany)

Serono SA (Switzerland; NYSE:SRA)

Agreement in which Serono will provide Graffinity with five target proteins related to treating major diseases in fields that range from immunology to reproductive health

The partnership could bring Graffinity up to |40M (US$42.9M) in up-front and milestone payments, as well as potential royalties (4/3)

Gyros
AB* (Sweden)

Cellectricon AB* (Sweden)

Patent agreement covering the manufacture and use of elastomeric microfluidic devices

Financial terms were not disclosed (4/14)

Gyros
AB* (Sweden)

Fluidigm Corp.*

Licensing agreement for a patent family that covers the development of certain microfluidic devices based on elastomeric layers

Further details were not disclosed (3/18)

Immuno-Designed Molecules* (France)

Jenner Biotherapies Inc.*

Agreement in which IDM acquired certain assets from Jenner

The assets concern the recombinant KSA antigen, better known as EP-CAM, which is expressed in a number of cancers; IDM will develop it for prostate cancer; IDM also acquired other antigens and the rights to immunopotentiators (4/9)

Inpharmatica
Ltd.* (UK)

Chiron
Corp. (CHIR)

Research program for Chiron to apply Inpharmatica's PharmaCarta chemogenomics platform to its protein targets for drug discovery

Financial terms were not disclosed (2/24)

Interferon Sciences Inc. (OTC BB:IFSC)

Hemispherx Biopharma Inc. (AMEX:HEB)

Agreement in which Hemispherx acquired certain assets from Interferon, including the rights to its drug, the Alferon N Injection, approved for venereal warts

Hemispherx also will acquire rights to experimental alpha-interferon products and all Interferon Sciences' interferon- related patents, licenses, clinical data and forward revenues; Interferon Sciences will receive Hemispherx stock, worth about $1.35M and an additional 125,000 shares; Hemispherx will assume $300,000 in payables from Interferon Sciences and take on $1.5M in debt through the deal (3/12)

Interleukin Genetics Inc. (OTC BB:ILGN)

Alticor Inc.*

Alliance to develop personalized nutritional and skin care products

Interleukin Genetics will provide intellectual property and its genomics knowledge to nutritional supplement-focused units of Alticor, which will take a majority equity stake in Interleukin (3/6)

Intronn Inc.*

ProBioGen AG* (Germany)

Collaboration to use Intronn's Spliceosome Mediated RNA Trans-splicing technology to enhance its internal research programs

ProBioGen plans to use the technology to improve its cell line development program (4/16)

Medarex Inc. (MEDX)

Diatos SA* (France)

Agreement for Diatos to license the cancer product Super-Leu-Dox

Diatos will provide prodrug peptide expertise; it has European rights to develop Super-Leu-Dox; Medarex has an option to buy back into the compound before it reaches Phase III development, and then co-develop and co-commercialize it in Europe (4/22)

Medarex Inc. (MEDX)

Ferric Technologies Inc.*

Collaboration for the research and development of fully human therapeutic antibodies

Ferric plans to use Medarex's UltiMAb Human Antibody Development System to generate antimicrobial antibodies; Ferric intends to develop and commercialize fully human antibody products for the treatment of bacterial diseases; Medarex could receive license fees and milestone payments as well as royalties on commercial sales of any products that result (2/27)

Medarex Inc. (MEDX)

Oncomab Ltd.* (subsidiary of PRIMaBioMed Ltd.; Australia)

Agreement to jointly develop fully human antibodies for cancer and to jointly commercialize any resulting products

Oncomab and Medarex expect to share equally the costs and potential revenues from the development of any antibody products (3/19)

Morphochem AG* (Germany)

Xenogen Corp.*

Multiyear research collaboration to discover targets and develop compounds effective against bacterial biofilms

Xenogen will develop in vitro and in vivo assays for gene targets directed against the formation and maintenance of biofilms, while Morphochem will work to identify compound classes as drug candidates for those targets (3/27)

NeoRx Corp. (NERX)

Boston Scientific Corp. (NYSE:BSX)

Agreement giving Boston Scientific an exclusive license to use NeoRx intellectual property, consisting of a portfolio of NeoRx patents cardiovascular field

The license grants Boston Scientific the right to use, in certain medical device fields, a separate portfolio of NeoRx patents and patent applications resulting from a collaboration with the University of Cambridge (4/21)

Oxford BioMedica plc (UK; LSE:OXB)

Viragen Inc. (AMEX:VRA)

Agreement for Viragen to obtain rights to a technology to develop avian transgenic technology as a platform for the efficient, cost-effective manufacturing of protein drugs

Agreement provides Viragen with an option to acquire an exclusive worldwide license for gene transfer vectors (3/18)

Paradigm Genetics Inc. (PDGM)

TissueInformatics Inc.*

Collaboration to discover biomarkers for chronic liver disease

Paradigm will perform metabolomics studies on tissue, urine and plasma to identify disease-specific biochemical profiles; TissueInformatics will perform automated, quantitative analyses of tissue histopathology to identify disease-specific changes in tissue structure; they will jointly market biomarkers that result (3/19)

Perlegen Sciences Inc.*

Unilever plc (UK; NYSE:UL)

Multiyear research collaboration under which the companies will use Perlegen's high-resolution whole-genome association technologies to develop consumer products

Perlegen will receive research funding, and would receive research success payments and royalties on product sales; Perlegen retains rights to develop therapeutic products based on the research results (2/21)

Phairson
Ltd.* (UK)

Life Medical Sciences Inc. (OTC BB:CHAI)

Agreement in which Life Medical acquired the polymer technology assets of Phairson

Phairson receives about 6.9M Life Medical common shares; Life Medical also assumed Phairson's rights and future royalty obligations under a license and development agreement with the Swiss Federal Institute of Technology and the University of Zurich (3/27)

PharmaStem Therapeutics Inc.*

Stembanc Inc.*

Agreement for PharmaStem to license its patent portfolio to Stembanc

Further details were not disclosed (2/20)

Primagen Holding BV* (the Netherlands)

OncoGenome Sciences SA* (Belgium)

Contract agreement to design and develop multiple molecular diagnostic tests for OncoGenome

Primagen will design five genomics-based diagnostic tests to detect cancer at earlier stages and more accurately than available tests (3/19)

Protein Design Labs Inc. (PDLI)

Actinium Pharmaceuticals Inc.*

Licensing agreement for certain rights to SMART M195

Actinium paid PDL an up-front licensing fee and is scheduled to pay development milestones and royalties (3/18)

Ricerca
Biosciences LLC*

PrimaScreen Inc.*

Strategic partnership designed to enhance Ricerca's ADME/ toxicology and metabolite identification capabilities

The capabilities will be enhanced by combining them with PrimaScreen's Validated Humanized Discovery toxicological assay platform (3/10)

Serenex Inc.*

MolecularNature Ltd.* (UK)

Agreement for Serenex to provide its chemoproteomic and Proteome Mining tech- nologies to screen an array of plant-derived compounds owned by MolecularNature

Both parties will decide on future drug development projects using high-potential compounds; they will share in intellectual property and revenue opportunities arising from the collaboration (4/22)

SurroMed Inc.*

InterMune Inc. (ITMN)

Agreement for the discovery of biomarkers for use in InterMune's research efforts

InterMune will supply clinical samples for analysis in SurroMed's BioMarker Discovery Laboratory; SurroMed will analyze the samples using its mass spectrometry-based technologies (3/4)

Tm Bioscience
Corp. (Canada; VSE:TMC)

LGC Ltd.* (UK)

Nonexclusive license agreement for the use of LGC's CYP2D6 gene patents in the Tag-It Mutation Detection kit for P450-2D6

The genetic test kit will be used to identify the presence or absence of mutations common in patients with atypical drug metabolism, which can lead to adverse drug responses (4/1)

Unigen Pharmaceuticals Inc.*

21st Century Therapeutics Inc.*

Collaboration for the discovery, development and commercialization of anticancer drugs targeted against solid tumors, including colon, lung, breast and prostate cancer

Unigen will supply 21st Century with botanical extracts, fractions and pure compounds for conducting a cellular assay in which drug leads are discovered and targeted to selectively inhibit tumor cell growth; Unigen will apply PhytoLogix to de-replicate the hit fractions and isolate solid tumor selective natural products for clonogenic, formulation and pharmacological studies at 21st Century (4/2)

Notes:

This chart does not include agreements that involve agricultural product development.

* Private companies are indicated with an asterisk.

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange